Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care, with some of the most important discussions focused on how to apply innovation in ways that meaningfully improve patient care. The presentations showcased increasingly complex sequencing decisions shaping blood cancer care. From data volume to decision quality and patient impactThe real test after EHA 2026 is not simply how much data the field can generate. But across the field, the direction is consistent: evidence needs to be generated with the end decision in mind. Prior to her role at Roche, she served as VP of clinical development oncology and infectious diseases at BioNTech SE, where she led clinical development and approval with Pfizer of the SARS-CoV-2 (COVID-19) vaccine.